Experimental drug

An experimental drug is a medicinal product (a drug or vaccine) that has not yet received approval from governmental regulatory authorities for routine use in human or veterinary medicine. A medicinal product may be approved for use in one disease or condition but still be considered experimental for other diseases or conditions. In 2018 the United States of America signed the legislation "Right to Try", this allows individuals who fit into the criteria to try experimental drugs that are not yet deemed safe.[1]

In the United States, the body responsible for approval is the U.S. Food and Drug Administration (FDA), which must grant the substance Investigational New Drug (IND) status before it can be tested in human clinical trials. IND status requires the drug's sponsor to submit an IND application that includes data from laboratory and animal testing for safety and efficacy.[2] A drug that is made from a living organism or its products undergoes the same approval process but is called a biologics license application (BLA). Biological drugs include antibodies, interleukins, and vaccines.

In Canada, a Clinical Trial Application (CTA) must be filed with the Health Products and Food Branch (HPFB) of Health Canada before starting a clinical trial. If the clinical trial results show that therapeutic effect of the drug outweighs negative side effects then the sponsor can then to file a New Drug Submission.[3]

Clinical trials in the European Union (EU) are regulated by the European Medicines Agency (EMA). Beginning in 2019 all applications for clinical trials must use a centralize EU portal and database. All clinical trial results will available to the public with the summary written in layperson's language.[4]

See also

References

  1. ↑ Mahant, Vijay (2020-06-23). ""Right-to-Try" experimental drugs: an overview". Journal of Translational Medicine. 18 (1): NA–NA.
  2. ↑ "How Drugs are Developed and Approved". U.S. Food and Drug Administration. Retrieved July 27, 2018.
  3. ↑ "How Drugs are Reviewed in Canada". Government of Canada. 8 January 2001. Retrieved July 27, 2018.
  4. ↑ "European Medicines Agency - Clinical Trials Regulation". European Medicines Agency. Archived from the original on July 30, 2018. Retrieved July 30, 2018.

    Public Domain This article incorporates public domain material from the U.S. National Cancer Institute document: "Dictionary of Cancer Terms".


    This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.